Ask the Doctor Question: What prognostic value is exon 15 braf mutation discovery with no tp53, no 17p, no trisonomy 12, no del 11q, but Unmutated status? Am I in line
CLL Society On Demand Ed Forum: ASH 2020 Comes to You – Session 3: New Combinations, New Sequences, New Ways to Measure Disease + CAR-T for Richters Recorded Thursday, February 4,
February 2026 CLL Bloodline: The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Dr. Meghan C. Thompson and Michele Nadeem-Baker joins us for CLL Society’s Facebook Live Event “Ask Me Anything”
The presence of certain precancerous mutations may predispose patients to increased risk of developing certain side effects in response to therapies.
Adding early Obinutuzumab to Acalabrutinib-Venetoclax significantly increases rates of uMRD in the bone marrow of patients with treatment-naïve CLL.
CLL Society awarded Dr. Matthews Davids a research grant for his project Optimizing Glofitamab Combination Therapy in Richter’s Transformation.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
The time-limited combination of duvelisib plus venetoclax was effective for treating relapsed / refractory CLL, but it also had significant side effects.
